Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol
- 1 November 2016
- journal article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 13 (11) , 1773-1777
Abstract
Introduction: One of the most serious known adverse effects of feminizing cross-sex hormone therapy (CSHT) is venous thromboembolism (VTE); however, no study has assessed the incidence of VTE from the hormone therapies used in the United States because previous publications on this topic have originated in Europe. CSHT in the United States typically includes estradiol with the antiandrogen spironolactone, whereas in Europe estradiol is prescribed with the progestin cyproterone acetate.Aim: To estimate the incidence of VTE from the standard feminizing CSHTs used in the United States.Methods: A retrospective chart review of transgender women who had been prescribed oral estradiol at a District of Columbia community health center was performed.Main Outcome Measure: The primary outcomes of interest were deep vein thrombosis or pulmonary emboli.Results: From January 1, 2008 through March 31, 2016, 676 transgender women received oral estradiol-based CSHT for a total of 1,286 years of hormone treatment and a mean of 1.9 years of CSHT per patient. Only one individual, or 0.15% of the population, sustained a VTE, for an incidence of 7.8 events per 10,000 person-years.Conclusion: There was a low incidence of VTE in this population of transgender women receiving oral estradiol.Keywords
This publication has 20 references indexed in Scilit:
- Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case–control studyEuropean Journal of Endocrinology, 2013
- A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormonesEuropean Journal of Endocrinology, 2011
- Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapyFertility and Sterility, 2010
- Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysisBMJ, 2008
- Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal ExperienceThe Journal of Clinical Endocrinology & Metabolism, 2008
- Hormone Therapy and Venous Thromboembolism Among Postmenopausal WomenCirculation, 2007
- Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism riskThe Lancet, 2003
- Short-Term and Long-Term Histologic Effects of Castration and Estrogen Treatment on Breast Tissue of 14 Male-to-Female Transsexuals in Comparison With Two Chemically Castrated MenAmerican Journal of Surgical Pathology, 2000
- Treatment of Advanced Prostatic Cancer with Parenteral Cyproterone Acetate: A Phase III Randomised Trial*British Journal of Urology, 1980
- Clinical Uses of Antiandrogens1974